ArticleHeliyon2025
Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of Janus kinase and TYK2 inhibitors in the treatment of generalized pustular psoriasis and palmoplantar pustulosis: a systematic review.Immunologic research · 2026Pooled it
- A review of current therapeutics for psoriasis: Systemic and topical use of non-biological drugs.European journal of clinical pharmacology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy and safety of Janus kinase (JAK) inhibitors as novel therapeutic agents for psoriasis (PSO) and psoriatic arthritis (PsA) have not yet been systematically evaluated. Methods: Randomized controlled studies (RCTs) assessing JAK inhibitors to treat PSO or PsA published before September 1, 2022, were searched in the PubMed, Embase, and Cochrane Library databases. The Psoriasis Area and Severity Index (PASI) 75 and American College of Rheumatology (ACR) 50 were established as primary outcome indicators of PSO and PsA, respectively. Adverse events (AEs) were classified according to eight systems of the human body. Results: We included 16 relevant RCTs involving 4,936 patients with psoriasis, with interventions performed using different doses of JAK inhibitors. Except in one study, all patients received a placebo or vehicle control. JAK inhibitors were administered topically in three studies and orally administered in the remaining studies. Meta-analysis revealed that oral administration of JAK inhibitors significantly improved PASI 75 in patients with PSO (risk ratio [RR] 3.29; 95 % confidence interval [CI] [2.37, 4.57]), and topical application was not effective (RR 1.45, 95 % CI [0.97, 2.15]). JAK1 and JAK3 inhibitors were more effective than JAK1/JAK 2 inhibitors for PASI 75. JAK1 inhibitors elicited high response rates in improving ACR 50 in PsA (RR 2.95, 95 % CI [1.63, 5.35]) and achieved significant results at week 16 of treatment (RR 2.95, 95 % CI [1.63, 5.35]). Oral JAK inhibitor-induced AEs were mainly related to the circulatory system (RR 3.09, 95 % CI [1.42, 6.75]). Conclusions: Oral JAK inhibitors improved clinical symptoms in patients with PSO. Tofacitinib, a JAK1 and JAK3 inhibitor, has a high response rate. Filgotinib, a JAK1 inhibitor, markedly enhanced the response rate and improved ACR scores in patients with PsA, and the best effect was achieved with 16-week oral administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.